NCT05768386
Hemophilia A, Hemophilia a
The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.
The BMN 270 clinical development program consists of multiple interventional studies designed to assess the safety and efficacy of a single infusion of BMN 270 for at least 5 years post-infusion. This long-term follow-up study is needed to help further understand the long-term safety of BMN 270 beyond 5 years and to assess the durability of efficacy.
Male
From 18 Years
No
Observational
172
2023-01-01
2024-04-24
Los Angeles, California, United States
Sacramento, California, United States
Shandon, California, United States
Aurora, Colorado, United States
Tampa, Florida, United States
Ann Arbor, Michigan, United States
Pittsburgh, Pennsylvania, United States
Cambridge, , United Kingdom
London, , United Kingdom
London, , United Kingdom
London, , United Kingdom
London, , United Kingdom
Southampton, , United Kingdom
By completing this form and clicking the send button, you understand and hereby consent to storage of your personal information, including within the United States and Europe, which will be accessible by BioMarin for purposes such as responding to your request, quality control, fulfilling compliance obligations, and assisting with products, services, or clinical trials. Depending on where you live, you may have the right to request access to, removal, or correction of your personal information held by BioMarin. You may submit your request via the contact information and/or webform located within the full BioMarin Privacy Policy.
*required fields
"*" indicates required fields